ScholarIQanswers from OpenAlex & ORCID
Melissa L. Johnson
ResearcherPublications, citations & collaboration network
Melissa L. Johnson is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Melissa L. Johnson have?
ScholarIQindexed works
Melissa L. Johnson has 859 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Melissa L. Johnson have?
ScholarIQcitation count
Melissa L. Johnson has 24,937 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Melissa L. Johnson?
ScholarIQh-index
Melissa L. Johnson has an h-index of 67 in OpenAlex.
What is the i10-index of Melissa L. Johnson?
ScholarIQi10-index
Melissa L. Johnson has an i10-index of 224 in OpenAlex.
What is the ORCID of Melissa L. Johnson?
ScholarIQorcid
The ORCID for Melissa L. Johnson is on the source record.
What is the OpenAlex record for Melissa L. Johnson?
ScholarIQopenalex
The OpenAlex for Melissa L. Johnson is on the source record.
What are the most-cited papers on Melissa L. Johnson?
ScholarIQmost cited works
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
Leora Horn, Aaron S. Mansfield, Aleksandra Szczęsna, Libor Havel, Maciej Krzakowski, Maximilian J. Hochmair, Florian Huemer, György Losonczy, Melissa L. Johnson, Makoto Nishio, Martin Reck, Tony Mok, Sivuonthanh Lam, David S. Shames, Juan Liu, Beiying Ding, Ariel López-Chávez, Fairooz F. Kabbinavar, Wei Lin, Alan Sandler, Stephen V. Liu
Adagrasib in Non–Small-Cell Lung Cancer Harboring a <i> KRAS <sup>G12C</sup> </i> Mutation
Pasi A. Jänne, Gregory J. Riely, Shirish M. Gadgeel, Rebecca S. Heist, Sai‐Hong Ignatius Ou, Jose M. Pacheco, Melissa L. Johnson, Joshua K. Sabari, Konstantinos Leventakos, Edwin Yau, Lyudmila Bazhenova, Marcelo V. Negrão, Nathan A. Pennell, Jun Zhang, Kenna Anderes, Hirak Der‐Torossian, Thian Kheoh, Karen Velastegui, Xiaohong Yan, James G. Christensen, Richard C. Chao, Alexander I. Spira
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
Alexander Drilon, Geoffrey R. Oxnard, Daniel Shao-Weng Tan, Herbert H. Loong, Melissa L. Johnson, Justin F. Gainor, Caroline E. McCoach, Oliver Gautschi, Benjamin Besse, Byoung Chul Cho, Nir Peled, Jared Weiss, Yu-Jung Kim, Yuichiro Ohe, Makoto Nishio, Keunchil Park, Jyoti D. Patel, Takashi Seto, Tomohiro Sakamoto, Ezra Y. Rosen, Manisha H. Shah, Fabrice Barlési, Philippe A. Cassier, Lyudmila Bazhenova, Filippo de Braud, Elena Garralda, Vamsidhar Velcheti, Miyako Satouchi, Kadoaki Ohashi, Nathan A. Pennell, Karen L. Reckamp, Grace K. Dy, Jürgen Wolf, Benjamin Solomon, Gerald S. Falchook, Kevin Ebata, Michele Nguyen, Binoj C. Nair, Edward Y. Zhu, Luxi Yang, Xin Huang, Elizabeth Olek, S. Michael Rothenberg, Kōichi Goto, Vivek Subbiah
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
Charles M. Rudin, M. Catherine Pietanza, Todd M. Bauer, Neal Ready, Daniel Morgensztern, Bonnie S. Glisson, Lauren A. Byers, Melissa L. Johnson, Howard A. Burris, Francisco Robert, Tae Hyung Han, Sheila Bheddah, Noah Theiss, Sky Watson, Deepan Mathur, Bharathi Vennapusa, Hany Zayed, Satwant Lally, Donald K. Strickland, Ramaswamy Govindan, Scott J. Dylla, Stanford L. Peng, David R. Spigel
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
Myung‐Ju Ahn, Byoung Chul Cho, Enriqueta Felip, Ippokratis Korantzis, Kadoaki Ohashi, Margarita Majem, Óscar Juan, Sabin Handzhiev, Hiroki Izumi, Jong Seok Lee, Rafał Dziadziuszko, Jürgen Wolf, Fiona Blackhall, Martin Reck, Jean Bustamante Alvarez, Horst-Dieter Hummel, Anne‐Marie C. Dingemans, Jacob Sands, Hiroaki Akamatsu, Taofeek K. Owonikoko, Suresh S. Ramalingam, Hossein Borghaei, Melissa L. Johnson, Shuang Huang, Sujoy Mukherjee, Mukul Minocha, Tony Jiang, Pablo Martínez, Erik S. Anderson, Luis Paz‐Ares